

October 21, 2016
SBI Biotech Co., Ltd.

**SBI Biotech's Licensed Product, an Anti-ILT7 Antibody (MEDI7734*) Has Achieved a
Developmental Milestone in a Phase I Clinical Trial**

SBI Biotech Co., Ltd. (Head office: Minato-ku, Tokyo; President: Takeshi Irie; "SBI Biotech") hereby announces that MedImmune (Head office: Gaithersburg, Md., USA), the global biologics research and development arm of AstraZeneca and the licensee, has started to dose patients with an anti-ILT7 antibody (MEDI7734*) in a Phase I Clinical Trial.

SBI Biotech and MedImmune entered into a licensing and collaboration agreement in September of 2008 to develop an antibody to the ILT7 antigen. Under the term of this agreement, SBI Biotech will now receive a milestone payment.

* MEDI7734 is MedImmune's development code for the Anti-ILT7 antibody.

About the anti-ILT7 antibody (MEDI7734)

ILT7 is a cell surface protein expressed on plasmacytoid dendritic cells (pDCs). The anti-ILT7 antibody (MEDI7734) has potential in treating autoimmune diseases.

For further information, please contact:
SBI Biotech Co., Ltd.
Business Planning Division
Phone number: +81-3-6229-0787